203 related articles for article (PubMed ID: 15760427)
1. Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model.
Mahamat A; Lavigne JP; Fabbro-Peray P; Kinowski JM; Daurès JP; Sotto A
Clin Microbiol Infect; 2005 Apr; 11(4):301-6. PubMed ID: 15760427
[TBL] [Abstract][Full Text] [Related]
2. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital.
Gallini A; Degris E; Desplas M; Bourrel R; Archambaud M; Montastruc JL; Lapeyre-Mestre M; Sommet A
J Antimicrob Chemother; 2010 Dec; 65(12):2650-7. PubMed ID: 20876240
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
[TBL] [Abstract][Full Text] [Related]
5. [E. coli: resistance to quinolones and beta-lactams of clinical strains isolated in the Franche-Comté region of France].
Talon D; Lallemand-De-Conto S; Thouverez M; Bertrand X
Pathol Biol (Paris); 2004 Mar; 52(2):76-81. PubMed ID: 15001235
[TBL] [Abstract][Full Text] [Related]
6. Comparison of minimum inhibitory concentration values for fluoroquinolones against Escherichia coli causing urinary tract infection in both hospitalized patients and outpatients.
Tayfour M; Yuce A; Yulug N
Saudi Med J; 2001 Oct; 22(10):848-51. PubMed ID: 11744939
[TBL] [Abstract][Full Text] [Related]
7. Emergence of ciprofloxacin resistance in Escherichia coli isolates from outpatient urine samples.
Gagliotti C; Nobilio L; Moro ML;
Clin Microbiol Infect; 2007 Mar; 13(3):328-31. PubMed ID: 17391392
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Gualco L; Schito AM; Schito GC; Marchese A
Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens.
Chenia HY; Pillay B; Pillay D
J Antimicrob Chemother; 2006 Dec; 58(6):1274-8. PubMed ID: 17040923
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
11. [Susceptibility to norfloxacin of some bacterial strains causing urinary infections].
Tuchiluş C; Poiată A; Bădicuţ I; Buiuc D
Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):383-6. PubMed ID: 16607805
[TBL] [Abstract][Full Text] [Related]
12. Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients.
Urbánek K; Kolár M; Strojil J; Koukalová D; Cekanová L; Hejnar P
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):741-5. PubMed ID: 15880441
[TBL] [Abstract][Full Text] [Related]
13. Emergence of fluoroquinolone resistance in Escherichia coli isolates at the department of clinical hematology.
Zemkova M; Kotlarova J; Merka V; Cermak P; Vlcek J; Jebavy L
New Microbiol; 2007 Oct; 30(4):423-30. PubMed ID: 18080678
[TBL] [Abstract][Full Text] [Related]
14. [Quinolone resistance of Escherichia coli strains isolated from urinary tract infections].
Agulla A; Montes I
Enferm Infecc Microbiol Clin; 1994; 12(6):322. PubMed ID: 8080877
[No Abstract] [Full Text] [Related]
15. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.
Cattoir V; Lesprit P; Lascols C; Denamur E; Legrand P; Soussy CJ; Cambau E
J Antimicrob Chemother; 2006 Nov; 58(5):1054-7. PubMed ID: 16984897
[TBL] [Abstract][Full Text] [Related]
16. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
[TBL] [Abstract][Full Text] [Related]
17. [Antimicrobial susceptibility of Proteus mirabilis urinary tract isolates from 1999 to 2005 at Nîmes University Hospital].
Mahamat A; Lavigne JP; Bouziges N; Daurès JP; Sotto A
Pathol Biol (Paris); 2006; 54(8-9):456-61. PubMed ID: 17030456
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of Romanian fluoroquinolone-resistant human clinical Escherichia coli isolates.
Usein CR; Tatu-Chiţoiu D; Nica M; Ciontea SA; Palade AM; Condei M; Damian M
Roum Arch Microbiol Immunol; 2008; 67(1-2):23-9. PubMed ID: 19284163
[TBL] [Abstract][Full Text] [Related]
19. The frequency of in vitro resistance to fluoroquinolones among clinical isolates of Escherichia coli.
Poiată A; Bădicuţ I; Grigore L; Buiuc D
Roum Arch Microbiol Immunol; 2000; 59(1-2):63-9. PubMed ID: 11845477
[TBL] [Abstract][Full Text] [Related]
20. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
Obana Y; Nishino T
Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
